Lipidsenkende Therapie bei chronischer Nierenerkrankung im Erwachsenenalter

ZUSAMMENFASSUNG

Die chronische Nierenerkrankung (CKD: „chronic kidney disease“) wird entsprechend der Leitlinien des Netzwerks Kidney Disease: Improving Global Outcomes (KDIGO) unabhängig von der Ätiologie definiert als mindestens 3-monatige Einschränkung der Nierenfunktion mit meist irreversibler, struktureller Schädigung der Nieren, die bis zur terminalen Niereninsuffizienz fortschreiten kann. Kardiovaskuläre Erkrankungen stellen die Haupttodesursache bei Patienten mit CKD dar. Mit abnehmender glomerulärer Filtrationsrate (GFR) steigt die Bedeutung nicht atherosklerotischer Risikofaktoren. Diese komplexe Risikokonstellation führt zu den 2 allgemeinen Therapiezielen: die Verhinderung oder Verlangsamung der Progredienz der CKD unter Einschluss der möglichst effektiven Behandlung der Grunderkrankung und der kardiovaskulären Prävention. Hinsichtlich der Atherosklerose ist die lipidsenkende Therapie (LLT: „lipid-lowering therapy“) ein wesentliches Element mit den Empfehlungen des KDIGO-Netzwerks und den Leitlinien der European Society of Cardiology (ESC) als Grundlagen.

Publication History

Article published online:
08 June 2023

• Literatur

• 1 Kidney Disease: Improving Global Outcomes KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl 2013; 03: 259-305
• 2 Matsushita K, van der Velde M, Astor BC. et al Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality: a collaborative meta-analysis of general population cohorts. Lancet 2010; 375: 2073-2081
• 3 Kaesler N, Schurgers LJ, Floege J. Vitamin K and cardiovascular complications in chronic kidney disease patients. Kidney Int 2021; 100: 1023-1036
• 4 Speer T, Schunk SJ, Fliser D. Chronische Nierenerkrankung – eine kardiovaskuläre Höchstrisikokonstellation. Internist 2020; 61: 340-348
• 5 Steiger S, Roissant J, Zarbock A. et al Secondary immunodeficiency related to kidney disease (SIDKD) – definition, unmet needs, and mechanisms. J Am Soc Nephrol 2022; 33: 259-278
• 6 Wanner C, Amann K, Shoji T. The heart and vascular system in dialysis. Lancet 2016; 388: 276-284
• 7 Aeschbacher-Germann M, Kaiser N, Speierer A. et al Lipid-lowering trials are not representative of patients managed in clinical practice: a systematic review and meta-analysis of exclusion criteria. J Am Heart Assoc 2023; 12: e026551
• 8 Esmeijer K, Dekkers OM, de Fijter JW. et al Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis. Sci Rep 2019; 09: 16632
• 9 Su X, Zhang L, Lv J. et al Effect of statins on kidney disease outcomes: a systematic review and meta-analysis. Am J Kidney Dis 2016; 67: 881-892
• 10 Walther CP, Richardson PA, Virani SS. et al Association between intensity of statin therapy and mortality in persons with chronic kidney disease. Nephrol Dial Transplant 2020; 35: 312-319
• 11 Shin JI, Fine DM, Sang Y. et al Association of rosuvastatin use with risk of hematuria and proteinuria. J Am Soc Nephrol 2022; 33: 1767-1777
• 12 Nissen SE, Lincoff AM, Brennan D. et al Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. New Engl J Med 2023; 388: 1353-1364
• 13 Charytan DM, Sabatine MS, Pedersen TR. et al Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. J Am Coll Cardiol 2019; 73: 2961-2970
• 14 Igweonu-Nwakile EO, Ali S, Paul S. et al A systematic review on the safety and efficacy of PCSK9 inhibitors in lowering cardiovascular risks in patients with chronic kidney disease. Cureus 2022; 14: e29140
• 15 Toth PP, Dwyer JP, Cannon CP. et al Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int 2018; 93: 1397-1408
• 16 Tunon J, Steg PG, Bhatt DL. et al Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEYOUTCOMES randomized clinical trial. Eur Heart J 2020; 41: 4114-4123
• 17 Lupo MG, Bressan A, Donato M. et al PCSK9 promotes arterial medial calcification. Atherosclerosis 2022; 346: 86-97
• 18 Ray KK, Raal FJ, Kallend DG. et al Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J 2023; 44: 129-138
• 19 Ference BA, Ginsberg HN, Graham I. et al Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. Eur Heart J 2017; 38: 2459-2472
• 20 Grundy SM, Cleeman JI, Merz CNB. et al Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227-239
• 21 Mach F, Baigent C, Catapano AL. et al 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188
• 22 Kronenberg F, Mora S, Stroes ESG. et al Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022; 43: 3925-3946
• 23 Bajaj A, Damrauer SM, Anderson AH. et al Lipoprotein(a) and risk of myocardial infarction and death in chronic kidney disease. Arterioscler Thromb Vasc Biol 2017; 37: 1971-87
• 24 Hopewell JC, Haynes R, Baigent C. The role of lipoprotein(a) in chronic kidney disease. J Lipid Res 2018; 59: 577-585
• 25 Collins R, Reith C, Emberson J. et al Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532-2561
• 26 Cholesterol Treatment Trialists’ (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681
• 27 Nicholls SJ, Puri R, Anderson T. et al Effect of evolocumab on progression of coronary disease in statin-treated patients – the GLAGOV randomized clinical trial. JAMA 2016; 316: 2373-2384
• 28 Baigent C, Landray MJ, Reith C. et al The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
• 29 Cholesterol Treatment Trialists’ (CTT) Collaboration Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 2016; 04: 829-839
• 30 Lamprea-Montealegre JA, Staplin N, Herrington WG. et al Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clin J Am Soc Nephrol 2020; 15: 47-60
• 31 Szummer K, Lundman P, Jacobson SH. et al Association between statin treatment and outcome in relation to renal function in survivors of myocardial infarction. Kidney Int 2011; 79: 997-1004
• 32 Matthew RO, Maron DJ, Anthopolos R. et al Guideline-directed medical therapy attainment and outcomes in dialysis-requiring versus nondialysis chronic kidney disease in the ISCHEMIA-CKD trial. Circ Cardiovasc Qual Outcomes 2022; 15: e008995
• 33 Rossing P, Caramori ML, Chan JCN. et al Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence. Kidney Int 2022; 102: 990-999
• 34 Wanner C. KDIGO-Leitlinien zum Lipidmanagement bei chronischen Nierenerkrankungen. Nephrologe 2014; 09: 46-47
• 35 Schneider MP, Hübner S, Titze SI. et al Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates. Kidney Int 2015; 88: 1411-1418
• 36 Visseren FLJ, Mach F, Smulders YM. et al 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol 2022; 29: 5-115
• 37 Gemeinsamer Bundesausschuss. Richtlinie des Gemeinsamen Bundesausschusses über die Verordnung von Arzneimitteln in der vertragsärztlichen Versorgung (Arzneimittel-Richtlinie/AM-RL) zuletzt geändert am 19. Januar 2023, veröffentlicht im Bundesanzeiger (BAnz AT 06.03.2023 B3)
• 38 Chen J, Budoff MJ, Reilly MP. et al Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease. JAMA Cardiol 2017; 02: 635-643
• 39 August P. Chronic kidney disease – another step forward. New Engl J Med 2023; 388: 179-180
• 40 Vart P, Vaduganathan M, Jongs N. et al Estimated lifetime benefit of combined RAAS and SGLT2 inhibitor therapy in patients with albuminuric CKD without diabetes. Clin J Am Soc Nephrol 2022; 17: 1754-1762
• 41 Kimura H, Tanaka K, Saito H. et al Association of polypharmacy with kidney disease progression in adults with CKD. Clin J Am Soc Nephrol 2021; 16: 1797-1804